Welcome To The Covalon Technologies Ltd HUB On AGORACOM

Advanced Medical Biosystems

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Message: Announces First Quarter Financial Results
Reply New Message
Back To Forum List View

Announces First Quarter Financial Results

posted on Feb 27, 2009 11:16AM
February 27, 2009
Covalon Technologies Ltd. Announces First Quarter Financial Results
MISSISSAUGA, ONTARIO--(Marketwire - Feb. 27, 2009) - Covalon Technologies Ltd. (TSX VENTURE:COV), an advanced biomedical systems company, today reported its fiscal 2009 first quarter financial results for the 3 months ended December 31, 2008. Total revenues for the quarter were $462,167, a decrease from the $930,893 reported in the first quarter of the 2008 fiscal year. Net loss was $1.3 million or $0.02 per share compared to a net loss of $676,007 or $0.01 per share for the first quarter of the 2008 fiscal year.

As at December 31, 2008, Covalon reported Cash equivalents held to support operations of $10.8 million and a working capital balance of $10.0 million.

Peter Hobbes, Covalon's CFO said, "Sales of our wound care products did not materialize as expected in this quarter while sales of our antimicrobial coatings saw some significant increase. We remain confident that investments in these two product lines as well as new business development projects we are working on will yield increased revenues in the future."

Dr. Frank DiCosmo, Covalon's President and CEO said, "We are working hard with our existing partners to grow our technology base already in the market. At the same time, we are diligently working on developing a number of new partnerships to significantly expand our technology offerings in the marketplace."

The Company's consolidated financial statements and MD&A for the first quarter ended December 31, 2008 are available at www.sedar.com and on the Company's website at www.covalon.com.

About Covalon

Covalon Technologies Ltd. is an advanced medical products company that has developed, patented and commercialized therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility, and microbial attachment.
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply